Telomir Pharmaceuticals, Inc. Common Stock beat EPS estimates 100% of the time across 2 reported quarters (2 beats, 0 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | — | $-0.79 | — | Miss |
| Q12026 FY2026 | $-0.07 | $-0.03 | +57.1% | Beat |
| Q42025 FY2025 | $-0.07 | $-0.06 | +14.3% | Beat |
| Q42025 FY2025 | $-0.07 | — | — | Miss |
Back to TELO overview · TELO holders · TELO KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.